Updated Perspectives on the Management of Multiple Myeloma in Older Patients: Focus on Lenalidomide
Kelly L Schoenbeck,1 Tanya M Wildes2 1Department of Medicine, University of California San Francisco, San Francisco, CA, USA; 2Department of Medicine, Washington University School of Medicine, St Louis, MO, USACorrespondence: Tanya M WildesDepartment of Medicine, Washington University School of Medi...
Guardado en:
Autores principales: | Schoenbeck KL, Wildes TM |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2020
|
Materias: | |
Acceso en línea: | https://doaj.org/article/8cb3971ce2e842908a06ec8e619aa443 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Cyclophosphamide-glucocorticoids versus lenalidomide-dexamethasone as treatment for multiple myeloma at first relapse after autologous stem cell transplantation – a retrospective analysis
por: Russell Sterrett, et al.
Publicado: (2021) -
Macroglossia reveals multiple myeloma
por: Maria Bonvicini, et al.
Publicado: (2021) -
Multiple myeloma in the very elderly patient: challenges and solutions
por: Willan J, et al.
Publicado: (2016) -
Therapy of Angiosarcoma with Thalidomide and Lenalidomide
por: M. Jules Mattes, et al.
Publicado: (2021) -
Suicide in older adults: current perspectives
por: Conejero I, et al.
Publicado: (2018)